| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026110325 |
| P356 | DOI | 10.1007/S12026-013-8409-8 |
| P698 | PubMed publication ID | 23572428 |
| P50 | author | Gisele Zandman-Goddard | Q73268900 |
| P2093 | author name string | Saakshi Khattri | |
| P2860 | cites work | Pleiotropic effects of statins | Q24647863 |
| Statin therapy and autoimmune disease: from protein prenylation to immunomodulation | Q28236647 | ||
| Small GTP-binding proteins | Q29547372 | ||
| Regulation of the mevalonate pathway | Q29547763 | ||
| The pathogenesis of rheumatoid arthritis | Q29614957 | ||
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | Q29616306 | ||
| Role of cytokines in rheumatoid arthritis | Q29620713 | ||
| Persistence with Statins and Onset of Rheumatoid Arthritis: A Population-Based Cohort Study | Q33691624 | ||
| Mortality trends in rheumatoid arthritis: the role of rheumatoid factor | Q33709660 | ||
| Non-lipid-related effects of statins | Q33924588 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Mortality in rheumatoid arthritis: 2008 update. | Q34014809 | ||
| Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation | Q34088380 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Atherosclerosis and systemic lupus erythematosus | Q34108806 | ||
| Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis | Q34283776 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Antiinflammatory and immunomodulatory properties of statins | Q34644504 | ||
| Isoprenoids as mediators of the biological effects of statins | Q34774535 | ||
| Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis | Q34776189 | ||
| Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? | Q34981331 | ||
| Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. | Q35553700 | ||
| High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis | Q36183213 | ||
| Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin | Q36228304 | ||
| NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis | Q36490904 | ||
| Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved | Q36628912 | ||
| Kawasaki Disease With Particular Emphasis on Arterial Lesions | Q36939820 | ||
| A randomized trial of rosuvastatin in the prevention of venous thromboembolism | Q37262627 | ||
| Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model | Q37362915 | ||
| The value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: do they imply new risk factors? | Q37674118 | ||
| Management of refractory anti-phospholipid syndrome | Q37874003 | ||
| Pathogenesis and therapies of immune-mediated myopathies | Q37881005 | ||
| Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. | Q37883018 | ||
| Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease | Q39851153 | ||
| Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers | Q39857638 | ||
| Therapy with statins in patients with refractory rheumatic diseases: a preliminary study | Q40551294 | ||
| Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study | Q42955705 | ||
| Statin therapy might be beneficial for patients with ankylosing spondylitis | Q42956017 | ||
| Effect of combining ACE inhibitor and statin in lupus-prone mice | Q43093252 | ||
| Statins for the treatment of antiphospholipid syndrome? | Q43275855 | ||
| Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering | Q43516483 | ||
| Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site | Q43625666 | ||
| Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | Q43837381 | ||
| The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease | Q43934617 | ||
| PPAR agonists amplify iNOS expression while inhibiting NF-kappaB: implications for mesangial cell activation by cytokines. | Q44111632 | ||
| A novel anti-inflammatory role for simvastatin in inflammatory arthritis | Q44285429 | ||
| Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model | Q44652593 | ||
| Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells | Q45033718 | ||
| Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice | Q45178632 | ||
| Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. | Q45822025 | ||
| Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study | Q46067922 | ||
| Effect of pravastatin on outcomes after cardiac transplantation. | Q46203599 | ||
| Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. | Q46614190 | ||
| Statins as immunomodulators in systemic sclerosis | Q46970276 | ||
| Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus | Q46973423 | ||
| Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. | Q50701881 | ||
| Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. | Q52574350 | ||
| Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q53040204 | ||
| The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. | Q54608986 | ||
| Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort | Q57804967 | ||
| Effects of pravastatin in murine collagen-induced arthritis | Q79375400 | ||
| A pravastatin dose-escalation study in systemic lupus erythematosus | Q80089099 | ||
| Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial | Q80784895 | ||
| Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis | Q80843926 | ||
| Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis | Q82263506 | ||
| Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin | Q83022894 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial | Q83393976 | ||
| Bilateral, simultaneous rupture of the quadriceps tendon associated with simvastatin | Q84185726 | ||
| P433 | issue | 2-3 | |
| P304 | page(s) | 348-357 | |
| P577 | publication date | 2013-07-01 | |
| P1433 | published in | Immunologic Research | Q15754981 |
| P1476 | title | Statins and autoimmunity | |
| P478 | volume | 56 |
| Q41882404 | A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate |
| Q38506851 | Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity |
| Q64262888 | Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form |
| Q52772414 | Cholesterol Accumulation in Dendritic Cells Links the Inflammasome to Acquired Immunity. |
| Q92616166 | Detection of Anti-mitochondrial Antibodies Accompanied by Drug-induced Hepatic Injury due to Atorvastatin |
| Q39293283 | Effects of Topical Atorvastatin (2 %) on Posthemorrhoidectomy Pain and Wound Healing: A Randomized Double-Blind Placebo-Controlled Clinical Trial |
| Q38177340 | Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk |
| Q59352740 | Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy: A Case Report |
| Q26853576 | Inflammation in arterial diseases |
| Q48072382 | Is statin use associated with new joint-related symptoms, physical function, and quality of life? Results from two population-based cohorts of women |
| Q33853966 | KLF2 is a rate-limiting transcription factor that can be targeted to enhance regulatory T-cell production |
| Q64946734 | Linking CD1-Restricted T Cells With Autoimmunity and Dyslipidemia: Lipid Levels Matter. |
| Q36330011 | Lovastatin blocks Kv1.3 channel in human T cells: a new mechanism to explain its immunomodulatory properties |
| Q36867309 | Neutrophil extracellular traps - the dark side of neutrophils |
| Q38711126 | Potential Immunomodulatory Effects of Statins in Inflammatory Bowel Disease |
| Q44832625 | Predictors of endothelial dysfunction in patients with rheumatoid arthritis |
| Q59313325 | Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis |
| Q35023243 | Statin use and markers of immunity in the Doetinchem cohort study |
| Q87656554 | Statins Associated With Decreased Risk of New Onset Inflammatory Bowel Disease |
| Q55402074 | The Role of Endothelial Progenitors in the Repair of Vascular Damage in Systemic Sclerosis. |
| Q57020491 | Topical atorvastatin 1% for prevention of skin toxicity in patients receiving radiation therapy for breast cancer: a randomized, double-blind, placebo-controlled trial |
| Q43734009 | Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle |
Search more.